These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 2967089)
1. Disposition of fosinopril sodium in healthy subjects. Singhvi SM; Duchin KL; Morrison RA; Willard DA; Everett DW; Frantz M Br J Clin Pharmacol; 1988 Jan; 25(1):9-15. PubMed ID: 2967089 [TBL] [Abstract][Full Text] [Related]
2. Disposition of zofenopril calcium in healthy subjects. Singhvi SM; Foley JE; Willard DA; Morrison RA J Pharm Sci; 1990 Nov; 79(11):970-3. PubMed ID: 2292772 [TBL] [Abstract][Full Text] [Related]
3. A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. Tu JI; Brennan J; Stouffer B; Eckelman WC Ther Drug Monit; 1990 Jul; 12(4):404-10. PubMed ID: 2144379 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. Duchin KL; Waclawski AP; Tu JI; Manning J; Frantz M; Willard DA J Clin Pharmacol; 1991 Jan; 31(1):58-64. PubMed ID: 1646240 [TBL] [Abstract][Full Text] [Related]
5. Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies. Morrison RA; Singhvi SM; Peterson AE; Pocetti DA; Migdalof BH Drug Metab Dispos; 1990; 18(2):253-7. PubMed ID: 1971582 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Hui KK; Duchin KL; Kripalani KJ; Chan D; Kramer PK; Yanagawa N Clin Pharmacol Ther; 1991 Apr; 49(4):457-67. PubMed ID: 1826651 [TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. Gehr TW; Sica DA; Grasela DM; Duchin KL Eur J Clin Pharmacol; 1993; 45(5):431-6. PubMed ID: 8112372 [TBL] [Abstract][Full Text] [Related]
8. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Sica DA; Cutler RE; Parmer RJ; Ford NF Clin Pharmacokinet; 1991 May; 20(5):420-7. PubMed ID: 1652404 [TBL] [Abstract][Full Text] [Related]
10. Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Gehr TW; Sica DA; Grasela DM; Fakhry I; Davis J; Duchin KL Eur J Clin Pharmacol; 1991; 41(2):165-9. PubMed ID: 1835932 [TBL] [Abstract][Full Text] [Related]
12. Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. Ding PY; Chu KM; Hu OY; Huang GM; Jeng JJ; Chang A; Delaney CL; MacAskill M; Yang BC; Jemal M; Smith R; Liao WC J Clin Pharmacol; 1999 Feb; 39(2):155-60. PubMed ID: 11563407 [TBL] [Abstract][Full Text] [Related]
13. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Murdoch D; McTavish D Drugs; 1992 Jan; 43(1):123-40. PubMed ID: 1372856 [TBL] [Abstract][Full Text] [Related]
14. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. O'Grady P; Yee KF; Lins R; Mangold B Br J Clin Pharmacol; 1999 Sep; 48(3):375-81. PubMed ID: 10510149 [TBL] [Abstract][Full Text] [Related]